📝 Rossari Biotech Limited — results explained
Quarter ended June 2026 (Q1 FY27)
Rossari Biotech Limited reported revenue of ₹697 crore for the quarter ended June 2026 (Q1 FY27), up 28.2% from ₹544 crore in the same quarter last year, and up 1.8% sequentially over the March 2026 quarter.
Net profit rose 4.5% year-on-year to ₹35 crore, from ₹34 crore. Earnings per share (EPS) came in at ₹6.34.
Operating profit stood at ₹81 crore — an operating margin (OPM) of 11.6%, compared with 12.5% in the year-ago quarter.
Full year and trailing twelve months
For the full year FY26, Rossari Biotech Limited posted revenue of ₹2,396 crore, a growth of 15.2% over FY25, with a net profit of ₹149 crore (up 9.9% year-on-year).
On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,550 crore with a net profit of ₹151 crore.
Valuation snapshot
At the current price of ₹454.65, ROSSARI has a market capitalisation of ₹2,518 crore and a trailing P/E of about 16.7.
Within the Chemicals industry, it is the 25th-largest of the 79 companies we track by market value.
Shareholding pattern
As of Sep 2026, promoters held 68.14%, foreign institutional investors (FIIs) 1.84%, domestic institutional investors (DIIs) 14.19%, public shareholders 15.83% of Rossari Biotech Limited.